The Effect of Rosuvastatin in a Murine Model of Influenza A Infection by Radigan, Kathryn A. et al.
The Effect of Rosuvastatin in a Murine Model of Influenza
A Infection
Kathryn A. Radigan
1*, Daniela Urich
1, Alexander V. Misharin
2, Sergio E. Chiarella
1, Saul Soberanes
1,
Angel Gonzalez
1, Harris Perlman
2, Richard G. Wunderink
1, G. R. Scott Budinger
1,3.,G o ¨khan M. Mutlu
1.
1Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 2Division of
Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 3Department of Cell and Molecular Biology,
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America
Abstract
Rationale: HMG-CoA reductase inhibitors such as rosuvastatin may have immunomodulatory and anti-inflammatory effects
that may reduce the severity of influenza A infection. We hypothesized that rosuvastatin would decrease viral replication,
attenuate lung injury, and improve mortality following influenza A infection in mice.
Methods: C57Bl/6 mice were treated daily with rosuvastatin (10 mg/kg/day) supplemented in chow (or control chow)
beginning three days prior to infection with either A//Udorn/72 [H3N2] or A/WSN/33 [H1N1] influenza A virus (1610
5 pfu/
mouse). Plaque assays were used to examine the effect of rosuvastatin on viral replication in vitro and in the lungs of
infected mice. We measured cell count with differential, protein and cytokines in the bronchoalveolar lavage (BAL) fluid,
histologic evidence of lung injury, and wet-to-dry ratio on Day 1, 2, 4, and 6. We also recorded daily weights and mortality.
Results: The administration of rosuvastatin had no effect on viral clearance of influenza A after infection. Weight loss, lung
inflammation and lung injury severity were similar in the rosuvastatin and control treated mice. In the mice infected with
influenza A (A/WSN/33), mortality was unaffected by treatment with rosuvastatin.
Conclusions: Statins did not alter the replication of influenza A in vitro or enhance its clearance from the lung in vivo. Statins
neither attenuated the severity of influenza A-induced lung injury nor had an effect on influenza A-related mortality. Our
data suggest that the association between HMG CoA reductase inhibitors and improved outcomes in patients with sepsis
and pneumonia are not attributable to their effects on influenza A infection.
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Introduction
Influenza is the leading cause of death from an infectious cause
and ranks 8
th in the list of attributable annual mortality in the
United States [1]. During the pandemic of 1918–1919, influenza
A virus caused as many as 50–100 million deaths [2]. In 2009, the
World Health Association (WHO) recognized a pandemic
infection with a newly identified strain of the influenza A virus
(H1N1). The Centers for Disease Control and Prevention (CDC)
estimated that 61 million cases, 274,000 hospitalizations, and
12,470 deaths were attributable to this strain in the United States
from April 2009 to April 2010 [3]. Fedson and Dunnill estimated
that 85% of developing countries were without vaccinations or
treatment during the recent pandemic [4].
Even if a vaccine is effective and the expected challenges in
generating an adequate supply are overcome, a substantial
percentage of the population will develop an influenza infection
during the next pandemic. Antiviral treatments are available but
these treatments are expensive, limited and may become
ineffective as resistant strains emerge [5,6]. For example, during
one of the most recent outbreaks in the United States, 185 of 190
H1N1 influenza virus isolates from 30 states were found to be
resistant to oseltamivir and investigators in Australia have recently
observed the emergence of oseltamivir resistant novel H1N1
strains [7,8].
In light of these concerns, alternative treatments that are readily
available and affordable are urgently needed. Inhibitors of HMG-
CoA reductase (or ‘‘statins’’) catalyze the conversion of hydro-
xymethylglutaryl-CoA to mevalonate and are widely used for
treatment of hyperlipidemia. In addition to their cholesterol
lowering effects, statins exert both anti-inflammatory and
immunomodulatory properties [9]. These effects are thought to
result from downstream effects of HMG-CoA reductase inhibition
on isoprenoid lipid production which may alter G-protein
signaling, cell proliferation, and the activity of adhesion molecules
[10]. In support of this hypothesis, several groups of investigators
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observational studies conducted in patients with sepsis and
bacterial pneumonia [11–20]. Rosuvastatin is one of the most
commonly prescribed HMG-CoA reductase inhibitors. We sought
to test the hypothesis that the administration of rosuvastatin to
mice would alter influenza A viral clearance or the clinical course
of influenza infection.
Methods
Ethics Statement
The protocol for the use of mice (ASP-2009-1041 and ASP-
2010-1938) was approved by the Animal Care and Use
Committee at Northwestern University.
Influenza A virus and cells
Influenza A virus (A//Udorn/72 [H3N2]) and (A/WSN/33
[H1N1]) were provided by Robert Lamb, Ph.D., Sc.D.,
Northwestern University, Evanston, IL. Madin-Darby Canine
Kidney (MDCK) cells (American Type Culture Collection
(ATCC), Manassas, VA) cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 1%
penicillin G/streptomycin and 10% fetal bovine serum (37uC,
5% CO2).
Viral plaque assay
We grew MDCK cells in 6-well plates to 70–90% confluency
and then treated them with DMEM supplemented with
rosuvastatin (5 mM) for 24 hours. Once the cells reached 100%
confluency, we incubated the cells with serial 10-fold dilutions of
influenza A virus (10
1–10
6 pfu) in DMEM and 1% bovine serum
albumin (BSA) at 37uC and aspirated the inoculums 1 hour later
[21]. We added 3 ml of replacement media [2.4% Avicel (FMC
BioPolymer, Philadelphia, PA), 26DMEM, and N-acetyl trypsin
(1.5 mg)] to each well and incubated them for 3 days [22]. We then
removed the overlay and visualized viral plaques using naphtha-
lene black dye solution (0.1% naphthalene black, 6% glacial acetic
acid, 1.36% anhydrous sodium acetate) [21,22].
Animals and administration of influenza A virus and
rosuvastatin
We used male C57BL/6 mice (8–12 weeks of age, 20–25 g)
from Charles River. We obtained rosuvastatin supplemented chow
formulations (485 mg/kg diet) from Harlan Laboratories. The
concentration of rosuvastatin in the chow was based on
measurements of daily chow intake in mice before and after
influenza A infection (3 and 1 g/day, respectively). The concen-
tration of chow was designed to provide 10 mg/kg/day of
rosuvastatin, which has been reported to achieve levels in mice
similar to those observed in humans and improve cardiovascular
endpoints in mice [23–25]. Three days after beginning rosuvas-
tatin supplementation, we anesthetized the mice with isoflurane
and intubated them using a 20 gauge angiocath [26]. We then
instilled 1610
5 pfu/ml of influenza A virus (A//Udorn/72
[H3N2]) or (A/WSN/33 [H1N1]) in 50 mL of PBS through the
catheter. We treated control mice with the same volume PBS. To
compensate for the decreased oral intake in the infected mice, the
influenza A infected mice were fed with a chow containing a 3-fold
higher concentration of rosuvastatin beginning 24 hours after
infection. Day 0 was defined as the day of infection. We weighed
unanesthetized mice on a portable balance (Mettler-Toledo Inc.,
Columbus, OH) daily.
Collection of bronchoalveolar lavage (BAL) fluid and
measurement of total protein, and cytokines
We sutured a 20-gauge angiocath into the trachea via a
tracheostomy and slowly infused and aspirated 0.8 mL of PBS
three times, which was immediately placed on ice. We then
centrifuged a 100 mL of the BAL fluid in a cytospin (1200 rpm for
5 minutes) and Wright stained the glass slides. We measured cell
count using a hemocytometer (trypan blue (0.4%) and subse-
quently counted the differential after staining was completed. We
centrifuged the remaining BAL fluid (2006 g, 5 min) and
measured BAL protein (Bradford) and cytokines (BD Cytometric
Bead Array Mouse Inflammation Kit, San Diego, CA) in the
supernatant [26].
Characterization of lung inflammatory cell populations
using flow cytometry
Mice were euthanized with Euthasol followed by a rapid
thoracotomy. The right ventricle was cannulated and while the
right atrium was clamped with forceps, 5 ml of PBS was infused.
The lungs were removed en bloc and the large airways were
dissected from the peripheral lung tissue. The latter was minced
and homogenized using Lung Dissociation kit (Miltenyl Biotek,
Auburn, CA, Catalogue #130-095-927) according to the
manufacturer’s instructions for 30 minutes at 37uC and passed
through 70 mm nylon mesh to obtain a single cell suspension.
Remaining red blood cells were lysed using BD Pharm Lyse (BD
Biosciences, San Jose, CA). Cells were counted using Countess
automated cell counter (Invitrogen, Carlsbad, CA); dead cells were
excluded using trypan blue.
After Live/Dead staining with Aqua dye (Invitrogen, Carlsbad,
CA), cells were incubated with FcBlock (BD Biosciences, San Jose,
CA) and stained with mixture of fluorochrome conjugated
antibodies (see Table S1 for the list of antibodies, clones,
fluorochromes and manufacturers). Data were acquired on BD
LSRII flowcytometer (BD Biosciences, SanJose, CA)(see Table S2
forinstrument configuration).Compensation and data analysiswere
performed using FlowJo software (TreeStar, Ashland, OR). After
gating out cell aggregates, debris and dead cells, immune cells were
identified using the pan-hematopoietic marker CD45. Specific cell
types were identified as follows: alveolar macrophages (highly
autofluorescent and CD11c
hiCD11b
int), interstitial macrophages
(CD11b
+CD11c
+MHC II
+/2), monocytes (CD11b
+CD11c
2Ly6C
+
MHC II
+/2), neutrophils (CD11b
+Ly6G
+), B cells (CD19
+), CD4 T
cells (CD4
+), CD8 T cells (CD8
+), NK cells (NK1.1
+), CD103
+
dendritic cells (CD11c
+CD11b
intMHC II
+CD103
+), CD103
2
dendritic cells (CD11c
+CD11b
+MHC II
+CD103
2). Data presented
as percent of cells in CD45
+ gate. Expression of the activation
markers presented as median fluorescence intensity (MFI).
Preparation of lung homogenates for viral plaque assay
We perfused the right ventricle in situ with sterile PBS (.1 ml,
until the lungs were clear). The lungs were removed and kept on
ice prior to and during homogenization (Tissue Tearor, 30 s) in a
flow cytometry tube with 1 ml of PBS. An additional 2 mL of PBS
was added to the resulting homogenate and subjected to Dounce
homogenization (20 strokes). The lung homogenate was centri-
fuged (4uC, 2000 rpm for 10 minutes). We then incubated the cells
with serial 10-fold dilutions of the supernatant in DMEM and 1%
bovine serum albumin (BSA) at 37uC and aspirated the inoculums
1 hour later [21]. We measured the viral titer in lung homogenates
as described above.
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We perfused the right ventricle in situ with sterile PBS (1 ml) and
then sutured a 20-gauge angiocath into the trachea via a
tracheostomy. We then removed the lungs en bloc and inflated
them to exactly 15 cm of H2O with 4% paraformaldehyde. We
examined 5 mm sections from paraffin embedded lungs stained
with hematoxylin-eosin using light microscopy. We evaluated the
lung water (edema) content by calculating the ratio of wet-to-dry
lung weights. Both left and right lungs were weighed before and
after oven desiccation (.72 hours) to calculate wet-to-dry lung
ratio.
Mortality
We continuously observed mice infected with influenza A virus
(A/WSN/33 [H1N1]) for signs of distress (slowed respiration,
failure to respond to cage tapping, failure of grooming and fur
ruffling). Mice that developed these symptoms were sacrificed and
the death was recorded as an influenza A-induced mortality. The
majority of the mice died without developing these signs, when this
occurred, the death was recorded as mortality.
Statistics
We explored differences between groups using analysis of
variance (ANOVA). When the ANOVA indicated a significant
difference, we explored individual differences using t tests with a
Dunnett or Tukey’s correction for multiple comparisons as
indicated. We performed all analyses using GraphPad Prism
version 4.00 for Windows (GraphPad Software, San Diego CA,
USA). Data are shown as means 6 SE. A p value,0.05 was
considered statistically significant for all tests.
Results
Rosuvastatin does not inhibit influenza A viral replication
in vitro or in vivo
To determine the appropriate concentrations of rosuvastatin in
the chow, we measured food intake in mice before and after
infection with Udorn or WSN strains of influenza A virus. Mice
treated with influenza A Udorn maintained a constant intake of
rosuvastatin at about 1/3 of the untreated value throughout the
duration of the experiment. Mice infected with influenza A WSN
stopped eating 2 days after infection. We used these values to
determine rosuvastatin intake in mice infected with either the two
strains of influenza A virus (Fig. 1A).
We infected mice with influenza A Udorn and measured viral
titers in lung homogenates obtained in the first 6 days after
infection. Viral titers were highest one day after infection and
declined thereafter (Fig. S1). We infected mice that had been
treated for 3 days with rosuvastatin supplemented chow with
Figure 1. Rosuvastatin does not inhibit influenza A viral replication in vitro or in vivo. (A) The oral intake of rosuvastatin by mice infected
with either Udorn or WSN strains of influenza A virus over time. We treated mice with rosuvastatin or control therapy starting 3 days before they were
infected with either Udorn or WSN strains of influenza A virus. Four days after influenza A infection, we measured viral titers (plaque forming unit
[pfu]) in lung homogenates harvested from mice treated with either (B) Udorn or (C) WSN strain. (D) Plaque forming units were counted in MDCK cells
treated with rosuvastatin (5 mM) beginning 24 hours prior to infection with influenza A virus (Udorn) in vitro.* P ,0.05 Udorn vs. PBS, WSN vs. PBS. NS;
not significant (Rosuvastatin vs. Control treatment).
doi:10.1371/journal.pone.0035788.g001
Statin and Influenza
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35788influenza A virus and collected lung homogenates 1, 2 and 4 days
later (Udorn) or 1 and 4 days later (WSN). There was no
significant difference in viral titers between the control and
rosuvastatin treated mice at any time point (Fig. 1B, Udorn;
Fig. 1C, WSN; only the day 4 value is shown; others are shown in
Figure S2). To determine whether rosuvastatin reduces influenza
A viral replication in vitro, we treated 70% confluent MDCK cells
with rosuvastatin in media or media alone (control) 24 hours
before the cells were infected with influenza A virus (Udorn) and
measured viral replication using plaque assays 72 hours later. We
observed no difference in viral replication between the control-and
rosuvastatin-treated cells (Fig. 1D).
Rosuvastatin does not alter the clinical course of
influenza A infection in mice
We treated mice with rosuvastatin prior to and following
infection with influenza A WSN as described above and followed
them for up to 14 days after infection and recorded mortality.
There were no significant differences in mortality between the
rosuvastatin or control treated mice (Fig. 2A). We then measured
weight loss in mice treated with rosuvastatin or control in the 10
days after infection with either Udorn or WSN strains of influenza
A virus. Infection with either strain of influenza A was associated
with the loss of approximately 30% of body weight. There was no
difference in influenza A-induced weight loss or recovery between
the rosuvastatin and control treated mice (Fig. 2B, Udorn; Fig. 2C,
WSN, mortality in the WSN treated mice precluded measure-
ments beyond 7 days).
Rosuvastatin does not have an effect on influenza A-
induced lung inflammation
We measured BAL fluid cell count in mice 4 days after infection
of mice with either Udorn or WSN strains of influenza A virus.
Similar to reports from other groups, we observed an increase in
BAL fluid cellularity (predominantly neutrophils and macrophag-
es) following infection with either strain of influenza virus. Total
leukocyte counts in the BAL fluid were similar in both the
rosuvastatin- and control-treated mice (Fig. 3A, Udorn; Fig. 3B,
WSN; other time points after infection shown in Figure S3A). We
then performed selected immunophenotyping of the inflammatory
cell populations (CD45
+) in lung digests. Infection with influenza A
caused a reduction in the relative percentage of alveolar
macrophages and an increase in the percentage of interstitial
macrophages, blood derived monocytes and neutrophils in the
lung (Fig. 3C). Influenza A infection also caused a reduction in
lymphocytes, an increase in monocyte-derived dendritic cells and
no significant change in natural killer cells or CD103
+ dendritic
cells in the lungs (Fig. S3B). Rosuvastatin treatment did not have
an effect on influenza A-induced changes in the percentage of
inflammatory cells (Fig. 3C and Fig. S3B).
Using flow cytometry, we also looked at expression of the
activation markers TLR4, TLR2, CD40, CD69, CD80, and
CD86 on alveolar macrophages (Fig. 4A), interstitial macrophages
(Fig. 4B), and monocyte-derived (CD103
2) dendritic cells (Fig. S4).
While influenza A infection was associated with increased
expression of all of these markers, there were no significant
differences between mice treated with rosuvastatin compared with
mice treated with control chow.
We then used a multiplex proinflammatory cytokine bead array
to measure the levels of pro-inflammatory cytokines in the BAL
fluid of mice infected 4 days earlier with either Udorn or WSN
strain of influenza A virus. Similar to reports from other
investigators, infection with influenza A was associated with an
increase in BAL fluid pro-inflammatory cytokines including TNF-
a (Fig. 5A, Udorn; Fig. 5B, WSN; other time points after infection
shown in Figure S5A) and IL-6 (Fig. 5C, Udorn; Fig. 5D, WSN;
other time points after infection shown in Figure S5B); however,
there were no significant differences in any of the cytokines
measured between control and rosuvastatin-treated mice (Fig. 5;
other cytokines are shown in Figure S5C).
Rosuvastatin does not modify the severity of influenza A-
induced lung injury
We treated mice with rosuvastatin beginning 3 days before
infection with the influenza A WSN virus and sacrificed the mice
for examination of hematoxylin and eosin stained lung sections on
Day 4 after infection. Compared with saline treated mice, we
Figure 2. Rosuvastatin does not alter the clinical course of
influenza A infection in mice. We treated mice with rosuvastatin or
control therapy starting 3 days before they were infected with either
Udorn or WSN strains of influenza A virus and measured (A) WSN-
associated mortality and (B) Udorn- and (C) WSN-associated changes in
daily weight.
doi:10.1371/journal.pone.0035788.g002
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and hemorrhage in the mice infected with either the influenza A
Udorn or WSN strains. However, there were no significant
differences in the histologic severity of the lung injury between the
influenza A-infected mice treated with rosuvastatin or control
chow (Fig. 6A, Udorn; Fig. 6B, WSN). Compared with control-
treated mice, we observed an increase in BAL fluid protein in
influenza A Udorn- or WSN-infected mice after infection (Fig. S6).
Again, there were no significant differences in BAL fluid protein
between mice treated with rosuvastatin or control chow (Fig. 6C,
Udorn; Fig. 6D, WSN; only Day 4 value is shown, others are
shown in Figure S6). Compared with control treated mice, we
observed an increase in wet-to-dry weight in mice treated with
influenza A WSN but not Udorn (Fig. S6). We saw no difference in
the increase in wet-to-dry weight ratio in the influenza A WSN-
treated mice treated with rosuvastatin (Fig. 6E).
Figure 3. Rosuvastatin does not have an effect on influenza A-induced changes in inflammatory cell count and differential in the
lungs. We treated mice with rosuvastatin or control therapy starting 3 days before they were infected with either Udorn or WSN strains of influenza A
virus. Four days after influenza A infection, (A, B) we measured cell count in the bronchoalveolar lavage fluid (BALF). (C) We also performed flow
cytometry in digested lung tissue from mice treated with WSN strain of influenza A virus to determine differential count of inflammatory cells
including alveolar and interstitial macrophages, monocytes and neutrophils. *P,0.05 Udorn vs. PBS, WSN vs. PBS. NS; not significant (Rosuvastatin vs.
Control treatment).
doi:10.1371/journal.pone.0035788.g003
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HMG-CoA reductase inhibitors are now the standard of care
for treating hyperlipidemia. Since their adoption into widespread
clinical use, several groups of investigators have reported apparent
benefits of statins in observational studies of patients with sepsis
and pneumonia, suggesting they may confer protection via a
mechanism independent of their lipid lowering effects [11–16,27].
In murine models of infection with two common strains of
influenza A virus, we found that orally administered rosuvastatin
did not alter influenza A viral replication in the lung, viral-
mediated inflammation, the development of acute lung injury or
mortality.
Several groups of investigators have suggested that some of the
benefit from statins result from an inhibition of inflammation [28–
32]. In normal volunteers, intranasal infection with influenza A
virus results in the release of TNF-a followed rapidly by the release
of IL-6 and other pro-inflammatory cytokines. In those patients,
nasal lavage and plasma levels of IL-6 best correlated with
influenza A symptoms [33]. In patients with a dilated cardiomy-
opathy, Node et al reported that the administration of statins was
associated with a reduction in the levels of TNF-a and IL-6 [34].
We therefore reasoned that the administration of statins would
Figure 4. Rosuvastatin does not alter the influenza A-induced expression of activation markers on inflammatory cells in the lungs.
We treated mice with rosuvastatin or control therapy starting 3 days before they were infected with WSN strains of influenza A virus. Four days after
influenza A infection, we performed flow cytometry in digested lung tissue to determine the effect of rosuvastatin on activation markers expressed
on (A) alveolar macrophages and (B) interstitial macrophages. *P,0.05 WSN vs. PBS. NS; not significant (Rosuvastatin vs. Control treatment).
doi:10.1371/journal.pone.0035788.g004
Statin and Influenza
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levels of these cytokines. However, we observed that the influenza-
A-induced increase in pro-inflammatory cytokines was similar in
mice treated with rosuvastatin and control treated mice.
Investigators have reported an inverse association between
statin use and poor clinical outcomes in observational studies of
patients with sepsis, community-acquired pneumonia (CAP),
bacteremia without sepsis, and in post-operative patients.
Furthermore, a recent randomized, open-label, controlled trial
showed a non-significant trend toward improved outcomes in
critically ill patients receiving statins [35]. While these benefits
may have resulted from the immunomodulatory or antimicrobial
effects of statins against certain pathogens [30–32], our results
suggest these effects would be minimal during influenza A
infection. Alternatively, the improved outcomes might result from
the well-established beneficial effects on statins on cardiovascular
outcomes. In support of this hypothesis, ischemic cardiovascular
complications are increasingly recognized as important contribu-
tors to pneumonia related morbidity and mortality [36–38].
Furthermore, in population based observational studies investiga-
tors have reported a positive association between influenza A
infection and an acute increase in cardiovascular and cerebrovas-
cular diseases, which drive a significant portion of the excess
mortality [36–38].
Statins may function as antimicrobials against some organisms.
For example the administration of statins has been shown to
prevent respiratory syncytial viral replication in vitro, perhaps as a
result of isoprenylation of RhoA, which binds to a viral fusion
glycoprotein required for RSV syncytium formation the admin-
istration [39]. RhoA and its binding to viral fusion glycoprotein
are necessary for RSV syncytium formation. Statins are known to
inhibit the production of isoprenyl groups and as a result prevent
its localization in the plasma membrane, limit entry, and attenuate
replication of RSV. Since the replication of influenza A virus is
different than RSV, it is not surprising that rosuvastatin had no
effect on the replication rate of Influenza A virus in vivo or in vitro.
In addition statins have been shown to inhibit the growth of
salmonella, yeast and the human immunodeficiency virus in vitro;
however, the in vivo relevance of these findings is unknown [40–
43]. We found that rosuvastatin did not alter influenza A viral
replication in vitro or change the rate of viral clearance in vivo.
We pretreated mice with rosuvastatin for 3 days prior to
influenza A infection and maintained this dose throughout the
infection in mice treated with Udorn strain. In these mice, we did
not observe any difference in the clinical course of influenza in the
control or rosuvastatin treated mice. However, in mice treated
with the WSN virus, oral intake virtually ceased 1–2 days after the
influenza infection and the mice became too ill to tolerate oral
gavage, precluding maintenance of the same dose. As a result, we
cannot exclude the possibility that a longer duration of
pretreatment or that maintenance of the dose in the premorbid
stages after infection with the WSN virus may have shown an
Figure 5. Rosuvastatin does not affect the influenza A-induced changes in pro-inflammatory cytokines in the lungs. We treated mice
with rosuvastatin or control starting 3 days before they were infected with either Udorn or WSN strains of influenza A virus. Four days after influenza
A infection, we collected bronchoalveolar lavage fluid (BALF) and measured (A, B) TNF-a and (C, D) IL-6 levels. *P,0.05 Udorn vs. PBS, WSN vs. PBS.
NS; not significant (Rosuvastatin vs. Control treatment).
doi:10.1371/journal.pone.0035788.g005
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rosuvastatin as a therapy in the early in the stages of influenza A
infection. We also speculate that the effect of statin therapy post-
infection would be negligible.
Weight loss is an important clinical component of influenza A
infection. Pro-inflammatory cytokines, including TNF-a, interleu-
kin (IL)-1b, and IL-6 have been implicated in the loss of appetite
and weight in influenza infection, chronic inflammatory disorders
and cancer [44–46]. In experimental models, reduced levels of
inflammatory cytokines have been shown to attenuate influenza A-
induced weight loss [46,47].
We conclude that in two murine models of influenza A
pneumonia, the administration of rosuvastatin did not alter the
viral clearance of influenza from the lung. Furthermore,
rosuvastatin did not attenuate the severity of influenza A-induced
lung injury and did not have an effect on influenza A related
mortality. Our results do not support the use of statins in patients
exposed to or diagnosed with acute influenza A infection who lack
other indications for their use.
Supporting Information
Figure S1 Influenza A viral titers in mouse lung tissue.
We infected mice with influenza A virus (Udorn) and measured
viral titers in lung homogenates obtained in the first 6 days after
infection.
(TIF)
Figure S2 The effect of rosuvastatin on influenza A viral
titers in mouse lung tissue. We treated mice with rosuvastatin
or control starting 3 days before they were infected with either
Udorn or WSN strains of influenza A virus and measured (A)
Udorn and (B) WSN viral titers (plaque forming unit) in lung
homogenates on day 1 (D1), D2 and D4 after infection.
(TIF)
Figure S3 The effect of rosuvastatin on influenza A-
induced changes in inflammatory cell count and differ-
ential in the lungs. We treated mice with rosuvastatin or
control therapy starting 3 days before they were infected with
Figure 6. Rosuvastatin does not modify the severity of influenza A-induced lung injury. We treated mice with rosuvastatin or control
starting 3 days before they were infected with either Udorn or WSN strains of influenza A virus. (A, B) Four days after influenza A infection, we
collected lungs for assessment of lung histology. Representative low (6100) and high (61,000) magnification images of lung sections from mice
treated with either the (A) Udorn or (B) WSN strains. (C, D) BALF protein concentrations in mice 4 days after infection with either the (C) Udorn or (D)
WSN strains. (E) Wet-to-dry weight ratio of lungs from mice 6 days after infection with the WSN strain. *P,0.05 Udorn vs. PBS, WSN vs. PBS. NS; not
significant (Rosuvastatin vs. Control treatment).
doi:10.1371/journal.pone.0035788.g006
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(A) Udorn- and (B) WSN-associated changes in the bronchoalve-
olar lavage fluid (BALF) cell count on day 1 (D1), D2, D4 and D6
after infection. (C) We also performed flow cytometry in digested
lung tissue from mice treated with WSN strain of influenza A virus
to determine differential count of inflammatory cells including
lymphocytes, dendritic cells and natural killer cells on day 4.
*P,0.05 WSN vs. PBS. NS; not significant (Rosuvastatin vs.
Control treatment).
(TIF)
Figure S4 Rosuvastatin does not alter the influenza A-
induced expression of activation markers on monocyte-
derived dendritic cells in the lungs. We treated mice with
rosuvastatin or control therapy starting 3 days before they were
infected with WSN strains of influenza A virus. Four days after
influenza A infection, we performed flow cytometry in digested
lung tissue to determine the effect of rosuvastatin on activation
markers expressed on monocyte-derived dendritic cells. *P,0.05
WSN vs. PBS. NS; not significant (Rosuvastatin vs. Control
treatment).
(TIF)
Figure S5 The effect of rosuvastatin on influenza A-
induced changes in cytokines. We treated mice with
rosuvastatin or control starting 3 days before they were infected
with either Udorn or WSN strains of influenza A virus and
measured the bronchoalveolar lavage fluid (BALF) levels of (A)
TNF-a,( B) IL-6 and (C) other cytokines including monocyte
chemotactic protein-1 (MCP-1), IL-10 and interferon-gamma
(IFN-c) on day 1 (D1), D2, and D4 after infection.
(TIF)
Figure S6 The effect of rosuvastatin on influenza A-
induced lung injury. We treated mice with rosuvastatin or
control starting 3 days before they were infected with either Udorn
or WSN strains of influenza A virus and measured (A, B) Udorn-
and (C, D) WSN-associated changes in the (A, C) bronchoalveolar
lavage fluid (BALF) protein levels and (B, D) lung weight-to-dry
ratio on day 1 (D1), D2, D4 and D6 after infection.
(TIF)
Table S1 Antibodies used flow cytometric analysis.
(DOCX)
Table S2 Configuration of the BD LSR II instrument.
(DOCX)
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